This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Drs Boland and Gehrman Reply

Elaine M. Boland, PhD, and Philip R. Gehrman, PhD

Published: April 25, 2018

See letter by Stewart and article by Boland et al

This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Drs Boland and Gehrman Reply

To the Editor: We were happy to see Dr Stewart’s comments, as one of the primary goals of our article1 was to promote a continued dialogue about sleep deprivation as a therapeutic tool (ie, wake therapy) and model for the development of rapid and effective antidepressants. The author makes an important point, and while we highlighted the fact that the overwhelming majority of the studies included in our analysis did not include control groups, we did not examine the efficacy of comparison groups in the small number of studies that did randomize their subjects to comparison conditions. The data Dr Stewart provided are an appropriate and important contribution to this discussion.

We have 2 main points in response. First, it is difficult to define an adequate comparison group for sleep deprivation. It is not possible to blind subjects to condition since they know whether or not they are sleep deprived. Further, an appropriate comparator should be a condition that has the potential to exert rapid antidepressant effects akin to those produced by sleep deprivation. To our knowledge, no other treatment apart from ketamine produces such rapid effects, and head-to-head comparisons of sleep deprivation and ketamine have not been undertaken. In the randomized studies we included, there was also broad heterogeneity in duration of treatment, single versus multiple administrations of sleep deprivation, partial versus total deprivation, and variations in comparison medications (SSRIs as well as tricyclic antidepressants) that further muddy the picture of how sleep deprivation truly compares to known antidepressant treatments.

Our second point is related to the rapidity of the antidepressant effects of sleep deprivation. The studies cited by Dr Stewart assessed the effects antidepressant medication after several weeks of treatment, not the next day. So, while it may be true that overall efficacy of wake therapy is not superior to medication, we are not aware of any evidence of placebo effects that can lead to a 50% response rate overnight. We concede that claims of the significant effect of sleep deprivation cannot be accepted without the understanding of the possible contribution of placebo and demand effects on outcome; however, we continue to see great promise in the continued examination of the mechanisms of the antidepressant effects of sleep deprivation in the service of developing rapid, effective, and longer-lasting treatments for depression.

Reference

1. Boland EM, Rao H, Ginges DF, et al. Meta-analysis of the antidepressant effects of acute sleep deprivation. J Clin Psychiatry. 2017;78(8):e1020-e1034. PubMed CrossRef

Elaine M. Boland, PhDa,b

Philip R. Gehrman, PhDa,b

[email protected]

aCorporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania

bDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

Potential conflicts of interest: None.

Funding/support: None.

J Clin Psychiatry 2018;79(2):17lr12018a

To cite: Boland EM, Gehrman PR. Drs Boland and Gehrman reply. J Clin Psychiatry. 2018;79(2):17lr12018a.

To share: https://doi.org/10.4088/JCP.17lr12018a

© Copyright 2018 Physicians Postgraduate Press, Inc.

Volume: 79

Quick Links: Psychiatry